Last reviewed · How we verify

complicated intra-abdominal infections caused by Escherichia coli — Treatment Landscape & Competitive Intelligence

complicated intra-abdominal infections caused by Escherichia coli (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating complicated intra-abdominal infections caused by Escherichia coli, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xerava ERAVACYCLINE Tetraphase Pharms 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Tetraphase Pharms · 1 drug in complicated intra-abdominal infections caused by Escherichia coli

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in complicated intra-abdominal infections caused by Escherichia coli:

Cite this brief

Drug Landscape (2026). complicated intra-abdominal infections caused by Escherichia coli — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-intra-abdominal-infections-caused-by-escherichia-coli. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing